Cargando…

Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver?

Lung carcinoids are well-differentiated and low-/intermediate-grade neuroendocrine neoplasms of the lung. Given their relative rarity, and the paucity of data available from prospective studies, no global consensus exists on the systemic treatment of these tumours. In recent years, immune checkpoint...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Molfetta, Sergio, Feola, Tiziana, Fanciulli, Giuseppe, Florio, Tullio, Colao, Annamaria, Faggiano, Antongiulio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876213/
https://www.ncbi.nlm.nih.gov/pubmed/35207291
http://dx.doi.org/10.3390/jcm11041019
_version_ 1784658112922255360
author Di Molfetta, Sergio
Feola, Tiziana
Fanciulli, Giuseppe
Florio, Tullio
Colao, Annamaria
Faggiano, Antongiulio
author_facet Di Molfetta, Sergio
Feola, Tiziana
Fanciulli, Giuseppe
Florio, Tullio
Colao, Annamaria
Faggiano, Antongiulio
author_sort Di Molfetta, Sergio
collection PubMed
description Lung carcinoids are well-differentiated and low-/intermediate-grade neuroendocrine neoplasms of the lung. Given their relative rarity, and the paucity of data available from prospective studies, no global consensus exists on the systemic treatment of these tumours. In recent years, immune checkpoint inhibitors have revolutionized cancer management and are under evaluation in patients with diverse types of neuroendocrine neoplasms. The aim of this narrative review is to analyse all available data for the use of approved immune checkpoint inhibitors in patients with lung carcinoids. We performed an extensive search for relevant data sources and found five published articles, one meeting abstract, and nine registered clinical trials indicating a growing interest of researchers in this field, and providing preliminary evidence of efficacy for combined nivolumab plus ipilimumab and durvalumab plus tremelimumab regimens in the treatment of advanced and/or metastatic lung carcinoids.
format Online
Article
Text
id pubmed-8876213
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88762132022-02-26 Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver? Di Molfetta, Sergio Feola, Tiziana Fanciulli, Giuseppe Florio, Tullio Colao, Annamaria Faggiano, Antongiulio J Clin Med Review Lung carcinoids are well-differentiated and low-/intermediate-grade neuroendocrine neoplasms of the lung. Given their relative rarity, and the paucity of data available from prospective studies, no global consensus exists on the systemic treatment of these tumours. In recent years, immune checkpoint inhibitors have revolutionized cancer management and are under evaluation in patients with diverse types of neuroendocrine neoplasms. The aim of this narrative review is to analyse all available data for the use of approved immune checkpoint inhibitors in patients with lung carcinoids. We performed an extensive search for relevant data sources and found five published articles, one meeting abstract, and nine registered clinical trials indicating a growing interest of researchers in this field, and providing preliminary evidence of efficacy for combined nivolumab plus ipilimumab and durvalumab plus tremelimumab regimens in the treatment of advanced and/or metastatic lung carcinoids. MDPI 2022-02-16 /pmc/articles/PMC8876213/ /pubmed/35207291 http://dx.doi.org/10.3390/jcm11041019 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Di Molfetta, Sergio
Feola, Tiziana
Fanciulli, Giuseppe
Florio, Tullio
Colao, Annamaria
Faggiano, Antongiulio
Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver?
title Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver?
title_full Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver?
title_fullStr Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver?
title_full_unstemmed Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver?
title_short Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver?
title_sort immune checkpoint blockade in lung carcinoids with aggressive behaviour: one more arrow in our quiver?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876213/
https://www.ncbi.nlm.nih.gov/pubmed/35207291
http://dx.doi.org/10.3390/jcm11041019
work_keys_str_mv AT dimolfettasergio immunecheckpointblockadeinlungcarcinoidswithaggressivebehaviouronemorearrowinourquiver
AT feolatiziana immunecheckpointblockadeinlungcarcinoidswithaggressivebehaviouronemorearrowinourquiver
AT fanciulligiuseppe immunecheckpointblockadeinlungcarcinoidswithaggressivebehaviouronemorearrowinourquiver
AT floriotullio immunecheckpointblockadeinlungcarcinoidswithaggressivebehaviouronemorearrowinourquiver
AT colaoannamaria immunecheckpointblockadeinlungcarcinoidswithaggressivebehaviouronemorearrowinourquiver
AT faggianoantongiulio immunecheckpointblockadeinlungcarcinoidswithaggressivebehaviouronemorearrowinourquiver
AT immunecheckpointblockadeinlungcarcinoidswithaggressivebehaviouronemorearrowinourquiver